KNOXVILLE, Tenn., Jan. 26, 2021 /PRNewswire/ — Integrity Laboratories announced today, the launch of the first commercially available quantitative index to accompany positive COVID-19 specimen resulted through their EUA approved platform. The feature, known as AmpliteCt™, is a viral load indicator (VLI) and is achieved through an automated, quantitative methodology that categorizes the concentration of viral genetic material in a patient specimen. The AmpliteCt™ algorithm leverages several key data points, including cycle threshold (Ct), to accurately stratify COVID-19 positive patients within low, moderate, or high infection designations.
“The AmpliteCt™ Viral Load Indicator utilizes the ability of a real time reverse transcriptase polymerase chain reaction (RT-PCR) technology to quantify the pathogen’s genetic material in a patient sample in a very short time with high sensitivity and specificity, “said Maria Cekanova, RNDr, Ph.D, Chief Scientific Officer for Integrity Laboratories. “We are excited to begin deploying this much needed advancement in technology to our healthcare partners.”
AmpliteCt™ VLI was developed by GenomIQ, a division of Integrity Laboratories focused on research and innovation of novel diagnostic technologies. Work began on the quantitative based approach to COVID-19 in September and was accelerated in conjunction with existing healthcare partnerships and validation studies.
“The AmpliteCt™ technology advancement into viral load visibility is game changing for clinicians as they seek to triage the clinical needs of their patients,” Said Christian Clevenger, Integrity Laboratories Chief Executive Officer. “Having access to quantifiable indexing also helps to identify those that may be candidates for viral load mediated therapies such as convalescent plasma. We are very proud of our team and their pioneering work in advancing diagnostic accuracy for COVID-19.”
ABOUT INTEGRITY LABORATORIES
Integrity Laboratories is the leading biotechnology firm committed to modernizing infectious disease management through high-complexity clinical diagnostics. Integrity Laboratories has pioneered antimicrobial stewardship with the introduction of Intercept PCR™, a molecular diagnostics platform that enables providers to order same-day and next-day diagnostic data on complicated patient conditions through non-invasive methods. Integrity Laboratories partners with the most trusted healthcare systems, providers, and insurance networks to deliver best-in-class technologies that lower costs and improve outcomes.
Media Contact:
Kelly Allen
289960@email4pr.com
1-844-658-5745 x110
SOURCE Integrity Laboratories
